0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
This Month in Archives of Dermatology |

This Month in Archives of Dermatology FREE

[+] Author Affiliations

Section Editor: Robin L. Travers, MD


Arch Dermatol. 2010;146(6):597. doi:10.1001/archdermatol.2010.126.
Text Size: A A A
Published online

FATAL INFLUENZA A(H1N1) RESPIRATORY TRACT INFECTION IN A PATIENT HAVING PSORIASIS TREATED WITH INFLIXIMAB

Biologic agents have revolutionized therapy for moderate to severe psoriasis. Although an increased infection risk has been associated with these agents, this risk may be balanced by overall decreased mortality and improved quality of life. In this case report, Kling et al describe an obese woman, previously treated with efalizumab over 3 years, who died from influenza A(H1N1) viral infection 1 week after her first infliximab infusion. Although no causal relationship can be proven, it is prudent to suggest annual inactivated influenza vaccine for patients being treated with biologic agents. Patients should be encouraged to report any upper respiratory symptoms early.

See Article

ADVERSE EVENTS FOLLOWING SMALLPOX VACCINATION WITH ACAM2000 IN A MILITARY POPULATION

Ongoing bioterrorism threats make smallpox vaccination for high-risk persons essential. A second-generation smallpox vaccine, ACAM2000, was approved by the US Food and Drug Administration in 2007. Although generalized vaccinia (GV) and benign cutaneous eruptions are well described following the old smallpox vaccine, risks with ACAM2000 remain unclear. In this case series, Beachkofsky et al review 8 cases of cutaneous reactions following ACAM2000 vaccination, confirming the first case of GV following this vaccine. In addition, 7 cases of a benign, acral, papulovesicular eruption were described. Immunohistochemical antibodies directed against vaccinia proteins may help identify deposits within biopsy specimens of these eruptions.

See Article

EPIDEMIOLOGY OF EPIDERMOLYSIS BULLOSA IN THE ANTIPODES

Epidermolysis bullosa (EB) is a group of genodermatoses characterized by excessive susceptibility of the skin to separate from underlying tissues following minimal mechanical trauma. While several EB registries exist, no epidemiologic or clinical data have previously been published for Australasian patients with EB. In this review of demographic and prognostic data obtained from the Australasian EB Registry, Kho et al verified that the nationwide prevalences of junctional EB (JEB) and dystrophic EB were consistent with those found in epidemiologic studies performed overseas. Epidermolysis bullosa simplex prevalence was lower, its milder phenotype possibly contributing to underreporting. The JEB-Herlitz type was associated with a higher infant mortality rate than in the United States, which may reflect parental wishes for nonaggressive management. Despite the limited number of JEB-Herlitz cases, this Australasian cohort remains one of the largest series ever reported to date.

See Article

SKIN MANIFESTATIONS AND VASCULAR ENDOTHELIAL GROWTH FACTOR LEVELS IN POEMS SYNDROME

POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes) is a rare plasma cell disorder. While the skin findings do not influence prognosis, their recognition helps confirm diagnosis. Many reports highlight the key pathologic role of elevated levels of serum vascular endothelial growth factor (VEGF-A). In this case series, Barete et al demonstrate that, despite some effect of VEGF-A levels in skin manifestations, the impact of lowered levels following autologous peripheral blood stem cell transplantation was weak. The authors suggest that facial lipoatrophy and livedo should be added to the skin manifestations of POEMS syndrome.

See Article

FOLLICULOTROPIC MYCOSIS FUNGOIDES

Folliculotropic mycosis fungoides (MF) is an uncommon MF subtype characterized by neoplastic lymphoid cell infiltration of the hair follicle. Folliculotropic MF may have a more aggressive natural history than other forms. In this case series, Lehman et al review the clinical and histopathologic features of folliculotropic MF cases seen over 12.5 years at the Mayo Clinic. Distinct clinical features and histopathologic findings are described. Folliculotropic MF was found to be less responsive to treatment than classic MF, with a relatively poor 5-year overall survival rate.

See Article

Tables

References

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

235 Views
0 Citations
×

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs